Outcomes of primary therapy
| Outcome . | MMF (n = 74) . | Placebo (n = 77) . |
|---|---|---|
| Treatment success within 2 y, n (%) | 11 (15) | 10 (13) |
| Treatment success after 2 y, n (%) | 0 (0) | 3 (4) |
| Treatment failure, n (%) | 43 (58) | 38 (49) |
| Secondary systemic therapy, n (%) | 24 (32) | 25 (32) |
| Development of bronchiolitis obliterans, n (%) | 5 (7) | 4 (5) |
| Recurrent malignancy, n (%)* | 13 (18) | 8 (10) |
| Death, n (%)* | 1 (1) | 1 (1) |
| Continuing primary therapy for > 2 y, n (%)† | 2 (3) | 2 (3) |
| Continuing primary therapy for < 2 y, (%)† | 18 (24) | 24 (31) |
| Outcome . | MMF (n = 74) . | Placebo (n = 77) . |
|---|---|---|
| Treatment success within 2 y, n (%) | 11 (15) | 10 (13) |
| Treatment success after 2 y, n (%) | 0 (0) | 3 (4) |
| Treatment failure, n (%) | 43 (58) | 38 (49) |
| Secondary systemic therapy, n (%) | 24 (32) | 25 (32) |
| Development of bronchiolitis obliterans, n (%) | 5 (7) | 4 (5) |
| Recurrent malignancy, n (%)* | 13 (18) | 8 (10) |
| Death, n (%)* | 1 (1) | 1 (1) |
| Continuing primary therapy for > 2 y, n (%)† | 2 (3) | 2 (3) |
| Continuing primary therapy for < 2 y, (%)† | 18 (24) | 24 (31) |